SNAP Message Board - Msg: 750878

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNAP

SNAP 7.300

-2.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: James Silverman who wrote (1)	2/1/1997 4:34:00 PM
From: scaram(o)uche	of 124

Patience? What is patience? It was interesting at H&Q. I expected that the NPY (fat drug, with Novartis) stuff would be the focus. Not even close. Kathleen Mullinex gets my vote as CEO of the meeting. She emphasized that all three partners have extended their agreements. The focus, of course, is G-protein coupled receptors. They have a second obesity project, for galanin, that is not yet partnered. The alpha andrenergic receptor program is Merck for BPH, and I _think_ (not clear on this) that she said that Dupont Merck and SNAP are working on an undisclosed target. But, the focus was seratonin-based drug design with Lilly. A project with Lilly is in phase I testing for migraine, and indications are that it doesn't have the side effects of Imitrex. Moreover, leads have been developed for anxiety and depression. Dr. Mullinex indicated that 1995 sales of seratonin-based drugs totaled $6 billion. She listed '97 goals at the end of the presentation. Number one was to do things the same as in '96. :-)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next